Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Amgen/Takeda VEGF Inhibitor Motesanib Faces Setback In NSCLC

This article was originally published in PharmAsia News

Executive Summary

Partners Amgen and Takeda have pinned near-term oncology growth prospects on motesanib, a vascular endothelial growth factor inhibitor for the treatment of non-small cell lung cancer. Now motesanib is facing a setback; Amgen announced Nov. 19 that the Phase III MONET-1 study has been temporarily suspended after a planned safety review showed earlier mortality rates in the treatment group

You may also be interested in...

Cancer Immunotherapy Sees Setback With Failure Of Takeda/Cell Genesys’ GVAX

Cell therapies have shown promise in treating cancer, but turning their possibility into reality so far has eluded the industry. Therefore, news Oct. 16 that one of the latest-stage therapies in development, Takeda/Cell Genesys' GVAX, failed in a second Phase III clinical trial represents, in some ways, a disappointment for the entire space

AstraZeneca’s Recentin Will Move Into Phase III For Colorectal Cancer, But Not NSCLC

Firm will study VEGF inhibitor plus chemotherapy versus Genentech’s Avastin in first-line colorectal cancer.

Bayer/Onyx’s Nexavar Falters In Lung-Cancer Phase III

Success eludes ESCAPE trial, stopped early by panel finding.

Related Content




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts